Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Sensitivity to isoniazid of Mycobacterium bovis BCG strains and BCG disseminated disease isolates.

Kolibab K, Derrick SC, Morris SL.

J Clin Microbiol. 2011 Jun;49(6):2380-1. doi: 10.1128/JCM.00648-11. Epub 2011 Apr 20. No abstract available.

2.

Antituberculous drug susceptibility testing of Mycobacterium bovis BCG strain Montréal.

Rousseau P, Dupuis M.

Can J Microbiol. 1990 Oct;36(10):735-7.

PMID:
2253115
3.

Evaluation of susceptibility of Mycobacterium bovis to antituberculous drugs by radiometric BACTEC 460TB system.

Cavirani S, Fanti F, Benecchi M, Calderaro A, Taddei S, Arcangeletti C, Medici MC, Dettori G, Chezzi C.

New Microbiol. 2003 Apr;26(2):181-6.

PMID:
12737201
4.

Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.

Larsen MH, Vilchèze C, Kremer L, Besra GS, Parsons L, Salfinger M, Heifets L, Hazbon MH, Alland D, Sacchettini JC, Jacobs WR Jr.

Mol Microbiol. 2002 Oct;46(2):453-66.

5.

Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.

Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N.

Antimicrob Agents Chemother. 2009 Jan;53(1):316-8. doi: 10.1128/AAC.01302-08. Epub 2008 Oct 27.

6.

[Distribution of the range of natural sensitivity to antitubercular preparations in cultures of strains of mycobacterum BCG].

Kulikova MF.

Antibiotiki. 1968 Jul;13(7):642-7. Russian. No abstract available.

PMID:
4301383
7.

In vitro susceptibility of Mycobacterium bovis against moxifloxacin.

Weiss T, Schönfeld N, Bettermann G, Blum TG, Kollmeier J, Mauch H, Bauer TT, Rüssmann H.

Int J Tuberc Lung Dis. 2012 Nov;16(11):1562. doi: 10.5588/ijtld.12.0042. No abstract available.

PMID:
23044455
8.

[Antitubercular effect of capreomycin in vitro].

Janowiec M.

Gruzlica. 1969 Jul;37(7):629-35. Polish. No abstract available.

PMID:
4981783
9.

Primary isoniazid resistance in Mycobacterium bovis disease: a prospect of concern.

McLaughlin AM, Gibbons N, Fitzgibbon M, Power JT, Foley SC, Hayes JP, Rogers T, Keane J.

Am J Respir Crit Care Med. 2012 Jul 1;186(1):110-1. No abstract available. Erratum in: Am J Respir Crit Care Med. 2012 Oct 15;186(8):807-8.

PMID:
22753693
10.

Editor's choice: Editorial commentary: Low level INH-resistant BCG: a sheep in wolf's clothing?

Arend SM, van Soolingen D.

Clin Infect Dis. 2011 Jan 1;52(1):89-93. doi: 10.1093/cid/ciq016. No abstract available.

PMID:
21148525
11.

Resistant Mycobacterium bovis disseminated infection.

Costa FF, Castro G, Andrade J, Jesus Ade R, de Almeida RP, Nascimento-Carvalho CM.

Pediatr Infect Dis J. 2006 Feb;25(2):190. No abstract available.

PMID:
16462308
12.

Anti-tuberculosis drug susceptibility testing of Mycobacterium bovis BCG Tokyo strain.

Shishido Y, Mitarai S, Otomo K, Seki M, Sato A, Yano I, Koyama A, Hattori T.

Int J Tuberc Lung Dis. 2007 Dec;11(12):1334-8.

PMID:
18034955
13.

Dielectrophoretic characterization of antibiotic-treated Mycobacterium tuberculosis complex cells.

Inoue S, Lee HB, Becker AL, Weigel KM, Kim JH, Lee KH, Cangelosi GA, Chung JH.

Anal Bioanal Chem. 2015 Oct;407(25):7673-80. doi: 10.1007/s00216-015-8928-3. Epub 2015 Aug 1.

PMID:
26231690
14.

In vitro drug susceptibility of Mycobacterium bovis BCG Connaught and Tokyo strains.

Shimizu T, Yasumoto K, Tatano Y, Tomioka H, Sato K, Sano C, Kumon H, Monden K.

J Infect. 2010 Mar;60(3):248-51. doi: 10.1016/j.jinf.2010.01.002. Epub 2010 Jan 13. No abstract available.

PMID:
20074586
15.

Pyrazinamide susceptibility testing in all isolates of the Mycobacterium tuberculosis complex - a critical analysis.

Cunha J.

Rev Port Pneumol. 2012 Jul-Aug;18(4):188-9. doi: 10.1016/j.rppneu.2011.12.002. Epub 2012 Jan 17. English, Portuguese. No abstract available.

16.

Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children.

Hesseling AC, Schaaf HS, Victor T, Beyers N, Marais BJ, Cotton MF, Wiid I, Gie RP, van Helden P, Warren RM.

Pediatr Infect Dis J. 2004 May;23(5):476-9.

PMID:
15131480
17.

Quantitative proteomics reveals novel insights into isoniazid susceptibility in mycobacteria mediated by a universal stress protein.

Hu X, Li X, Huang L, Chan J, Chen Y, Deng H, Mi K.

J Proteome Res. 2015 Mar 6;14(3):1445-54. doi: 10.1021/pr5011058. Epub 2015 Feb 18.

PMID:
25664397
18.

Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.

Watts MR, Taylor PC, Sintchenko V, Whelan CM, Farnsworth RH, Jones P, Jelfs P, Carr D, Goldberg H.

Clin Infect Dis. 2011 Jan 1;52(1):86-8. doi: 10.1093/cid/ciq002.

PMID:
21148524
19.

Human bovine tuberculosis - remains in the differential.

Bilal S, Iqbal M, Murphy P, Power J.

J Med Microbiol. 2010 Nov;59(Pt 11):1379-82. doi: 10.1099/jmm.0.020511-0. Epub 2010 Aug 5.

PMID:
20688950
20.

Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children.

Schaaf HS, Victor TC, Engelke E, Brittle W, Marais BJ, Hesseling AC, van Helden PD, Donald PR.

Eur J Clin Microbiol Infect Dis. 2007 Mar;26(3):203-5.

PMID:
17294161

Supplemental Content

Support Center